Change at the top for Biogen after Alzheimer’s drug flops
Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less ...
Read moreBiogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less ...
Read moreBiogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough ...
Read moreShares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker’s ...
Read moreBiogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to ...
Read more